The FDA has approved Truxima (rituximab-abbs), which is biosimilar to Rituxan (rituximab), for treating adults with CD20-positive, B-cell non-Hodgkin’s lymphoma…
Search results for: herpes zoster
Ustekinumab May Be Effective for Lupus
New research underscores the possibility that interleukin (IL) 12, IL-23 or both play roles in the immunopathology of SLE. In the study, when added to standard-of-care treatment for active SLE, ustekinumab demonstrated better efficacy than placebo and had a safety profile consistent with that of ustekinumab therapy in other diseases…
Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
AMSTERDAM—With new therapies coming into the marketplace, researchers are working to tease out the risk of infection for rheumatoid arthritis (RA) patients. Existing data suggest the risk of infections—even fatal ones—is real. But over time, improvements have taken hold, particularly for tuberculosis, according to an infectious disease expert at EULAR: the Annual European Congress of…
Investigators Assess Infection Risk with RA Biologics
Due to a range of factors, determining the precise infection risk posed by new biologic therapies to RA patients is difficult. But progress has been made and health registries may be helpful, said Olivier Lortholary, MD, PhD, during the 2018 EULAR: Annual European Congress of Rheumatology…
Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
New research shows tanezumab may be safe and effective for patients with osteoarthritis pain…
Results from Belimumab Safety Study
In a long-term extension study, belimumab proved safe, demonstrating low organ damage accrual in SLE patients treated for up to nine years…
FDA Approves Baricitinib for RA Patients
The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…
Upadacitinib Promising for RA in Phase 3 Study
In a recent study, upadacitinib proved safe and effective to treat rheumatoid arthritis in patients with inadequate responses to conventional synthetic DMARDs…
From the Front Lines: Managing RA Comorbidities in Primary Care
How are comorbidities for RA patients managed outside of rheumatology? A recent Canadian study developed and assessed quality measures related to preventive care and screenings for RA patients in a primary care setting, comparing RA and non-RA patients. The results: Primary care physicians often provide similar levels of care to patients with and without RA. But RA patients were less likely to receive some cancer screenings and all necessary tests to assess their cardiovascular risk…
Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity
NEW YORK (Reuters Health)—Tofacitinib begun two to three weeks after live zoster vaccination does not impair immunogenicity, and vaccination appears to be safe in patients with pre-existing varicella zoster virus (VZV) immunity, researchers report. Patients with rheumatoid arthritis (RA) are about twice as likely as healthy adults to develop herpes zoster, or shingles, and the…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 9
- Next Page »